You are here:

imatinib (Glivec)

Advice

following a full re-submission:

imatinib (Glivec) is accepted for restricted use within NHS Scotland.

Indication under review: adjuvant treatment of adult patients who are at significant risk of relapse following resection of a KIT (CD117) positive gastrointestinal stromal tumour (GIST).  Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.

SMC restriction: Imatinib is restricted to use in patients at high risk of recurrence following complete resection (according to the Armed Forces Institute of Pathology (AFIP) risk criteria).

Adjuvant imatinib therapy given for a period of three years compared to one year, significantly improved the recurrence free survival in adult patients at significant risk of relapse following resection of GIST.

The clinical and cost-effectiveness of three years adjuvant imatinib treatment was demonstrated.

Drug Details

Drug Name: imatinib (Glivec)
SMC Drug ID: 584/09
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Adjuvant treatment of adult patients who are at significant risk of relapse following resection of a KIT (CD117) positive gastrointestinal stromal tumour (GIST). Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Resubmission
Status: Restricted
Date Advice Published: 9 April 2012

Archived Advice

Resubmission 13 September 2010
Full submission 7 December 2009

Back